Dimebon (latrepirdine)    (DrugBank: Latrepirdine, Dimebon)

1 disease
IDDisease name (Link within this page)Number of trials
8Huntington disease10

8. Huntington disease    [ 197 clinical trials,   171 drugs,   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways]
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
10 / 197 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-018123-32-SE
(EUCTR)
30/09/201010/06/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
2EUCTR2009-018123-32-NL
(EUCTR)
23/08/201014/04/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
3EUCTR2009-018123-32-IT
(EUCTR)
28/07/201015/07/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-Plus Huntington`s Corea
MedDRA version: 9.1;Level: LLT;Classification code 10020469
Product Name: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Product Name: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
MEDIVATION, INC.NULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
4EUCTR2009-018123-32-DE
(EUCTR)
07/06/201002/03/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
5EUCTR2009-018123-32-GB
(EUCTR)
14/05/201018/03/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2009-018123-32-DK
(EUCTR)
23/04/201016/03/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
7NCT01085266
(ClinicalTrials.gov)
February 201010/3/2010An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseHuntington DiseaseDrug: Dimebon (latrepirdine)Medivation, Inc.Pfizer;PfizerTerminated30 YearsN/ABoth362Phase 3NULL
8NCT00988624
(ClinicalTrials.gov)
October 20091/10/2009A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)Alzheimer's Disease;Huntington DiseaseDrug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4PfizerMedivation, Inc.Completed18 Years55 YearsBoth20Phase 1United States
9NCT00990613
(ClinicalTrials.gov)
October 20096/10/2009A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinA Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older AdultsAlzheimer's Disease;Huntington's DiseaseDrug: Dimebon IR;Drug: Dimebon TransdermalPfizerMedivation, Inc.Completed50 Years85 YearsBoth19Phase 1United States
10NCT00975481
(ClinicalTrials.gov)
October 200910/9/2009A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersA Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersAlzheimer's Disease;Huntington's DiseaseDrug: dimebon;Drug: placebo;Drug: alprazolamPfizerMedivation, Inc.Completed18 Years55 YearsAll36Phase 1Canada